Early clinical experience with clonidine in spinal spasticity

The centrally active, alpha-2 adrenergic receptor agonist clonidine was given to 12 spinal cord injury patients with problematic spasticity not adequately controlled by recognized spasmolytic drug therapy. Five patients had an excellent reduction and 2 patients had some reduction in clinical spastic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Paraplegia 1986-06, Vol.24 (3), p.175-182
1. Verfasser: MAYNARD, F. M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 182
container_issue 3
container_start_page 175
container_title Paraplegia
container_volume 24
creator MAYNARD, F. M
description The centrally active, alpha-2 adrenergic receptor agonist clonidine was given to 12 spinal cord injury patients with problematic spasticity not adequately controlled by recognized spasmolytic drug therapy. Five patients had an excellent reduction and 2 patients had some reduction in clinical spasticity (average dose 0.39 mg daily). Four of the 7 responders discontinued clonidine because of adverse reactions after an average of ten weeks of therapy. Three responders have continued to tolerate the drug well with excellent control of spasticity for 18 to 34 months. Five patients had no change in clinical spasticity (average dose of 0.24 mg daily). Three of the non-responders discontinued clonidine because of adverse reactions after an average of three weeks of therapy. Significant associated adverse reactions included syncopal seizures (3), cerebrovascular accident (1), deep vein thrombosis (1), autonomic hyperreflexia (3), lethargy/drowsiness (3), and nausea/vomiting (1). Possible mechanisms of action for clonidine to affect spasticity and the unstable cardiovascular system of quadriplegics is discussed. While spinal cord injured patients with severe spasticity may benefit from clonidine, great caution is recommended during its use until further study establishes safe parameters of administration and efficacy is confirmed on controlled studies.
doi_str_mv 10.1038/sc.1986.24
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1038_sc_1986_24</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3748598</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-1c3a1591999a4e383103c62241d5062901686036b29c844f8c725698d4ebbf453</originalsourceid><addsrcrecordid>eNo9kL1LA0EUxBdRYohp7IUrrISL-31vCwsJiQoBG62PvXd7uHLZHLsnmv_eDQl5zSvmxzAzhNwyumBUwGPCBTOgF1xekCmTlS6V5vKSTCkVrGSVgmsyT-mb5tOKcg4TMhGVBGVgSp5WNvb7AnsfPNq-cH-Di94FdMWvH7-ysAu-9cEVPhRp8CEzabBp9OjH_Q256myf3Pz0Z-RzvfpYvpab95e35fOmRCGrsWQoLFOGGWOsdAJEDo6ac8laRTU3lGnQVOiGGwQpO8CKK22gla5pOqnEjDwcfTHuUoquq4fotzbua0brwwp1wvqwQs1lhu-O8PDTbF17Rk-ds35_0m3KlbtoA_p0xio4JALxDzM6YnI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Early clinical experience with clonidine in spinal spasticity</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>MAYNARD, F. M</creator><creatorcontrib>MAYNARD, F. M</creatorcontrib><description>The centrally active, alpha-2 adrenergic receptor agonist clonidine was given to 12 spinal cord injury patients with problematic spasticity not adequately controlled by recognized spasmolytic drug therapy. Five patients had an excellent reduction and 2 patients had some reduction in clinical spasticity (average dose 0.39 mg daily). Four of the 7 responders discontinued clonidine because of adverse reactions after an average of ten weeks of therapy. Three responders have continued to tolerate the drug well with excellent control of spasticity for 18 to 34 months. Five patients had no change in clinical spasticity (average dose of 0.24 mg daily). Three of the non-responders discontinued clonidine because of adverse reactions after an average of three weeks of therapy. Significant associated adverse reactions included syncopal seizures (3), cerebrovascular accident (1), deep vein thrombosis (1), autonomic hyperreflexia (3), lethargy/drowsiness (3), and nausea/vomiting (1). Possible mechanisms of action for clonidine to affect spasticity and the unstable cardiovascular system of quadriplegics is discussed. While spinal cord injured patients with severe spasticity may benefit from clonidine, great caution is recommended during its use until further study establishes safe parameters of administration and efficacy is confirmed on controlled studies.</description><identifier>ISSN: 0031-1758</identifier><identifier>ISSN: 1362-4393</identifier><identifier>EISSN: 1476-5624</identifier><identifier>DOI: 10.1038/sc.1986.24</identifier><identifier>PMID: 3748598</identifier><identifier>CODEN: PRPLBL</identifier><language>eng</language><publisher>Basingstoke: Macmillan</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Clonidine - adverse effects ; Clonidine - therapeutic use ; Female ; Humans ; Male ; Medical sciences ; Miscellaneous ; Muscle Spasticity - drug therapy ; Neuropharmacology ; Pharmacology. Drug treatments ; Quadriplegia - drug therapy</subject><ispartof>Paraplegia, 1986-06, Vol.24 (3), p.175-182</ispartof><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-1c3a1591999a4e383103c62241d5062901686036b29c844f8c725698d4ebbf453</citedby><cites>FETCH-LOGICAL-c347t-1c3a1591999a4e383103c62241d5062901686036b29c844f8c725698d4ebbf453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=7862908$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3748598$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MAYNARD, F. M</creatorcontrib><title>Early clinical experience with clonidine in spinal spasticity</title><title>Paraplegia</title><addtitle>Paraplegia</addtitle><description>The centrally active, alpha-2 adrenergic receptor agonist clonidine was given to 12 spinal cord injury patients with problematic spasticity not adequately controlled by recognized spasmolytic drug therapy. Five patients had an excellent reduction and 2 patients had some reduction in clinical spasticity (average dose 0.39 mg daily). Four of the 7 responders discontinued clonidine because of adverse reactions after an average of ten weeks of therapy. Three responders have continued to tolerate the drug well with excellent control of spasticity for 18 to 34 months. Five patients had no change in clinical spasticity (average dose of 0.24 mg daily). Three of the non-responders discontinued clonidine because of adverse reactions after an average of three weeks of therapy. Significant associated adverse reactions included syncopal seizures (3), cerebrovascular accident (1), deep vein thrombosis (1), autonomic hyperreflexia (3), lethargy/drowsiness (3), and nausea/vomiting (1). Possible mechanisms of action for clonidine to affect spasticity and the unstable cardiovascular system of quadriplegics is discussed. While spinal cord injured patients with severe spasticity may benefit from clonidine, great caution is recommended during its use until further study establishes safe parameters of administration and efficacy is confirmed on controlled studies.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Clonidine - adverse effects</subject><subject>Clonidine - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Muscle Spasticity - drug therapy</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Quadriplegia - drug therapy</subject><issn>0031-1758</issn><issn>1362-4393</issn><issn>1476-5624</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kL1LA0EUxBdRYohp7IUrrISL-31vCwsJiQoBG62PvXd7uHLZHLsnmv_eDQl5zSvmxzAzhNwyumBUwGPCBTOgF1xekCmTlS6V5vKSTCkVrGSVgmsyT-mb5tOKcg4TMhGVBGVgSp5WNvb7AnsfPNq-cH-Di94FdMWvH7-ysAu-9cEVPhRp8CEzabBp9OjH_Q256myf3Pz0Z-RzvfpYvpab95e35fOmRCGrsWQoLFOGGWOsdAJEDo6ac8laRTU3lGnQVOiGGwQpO8CKK22gla5pOqnEjDwcfTHuUoquq4fotzbua0brwwp1wvqwQs1lhu-O8PDTbF17Rk-ds35_0m3KlbtoA_p0xio4JALxDzM6YnI</recordid><startdate>198606</startdate><enddate>198606</enddate><creator>MAYNARD, F. M</creator><general>Macmillan</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>198606</creationdate><title>Early clinical experience with clonidine in spinal spasticity</title><author>MAYNARD, F. M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-1c3a1591999a4e383103c62241d5062901686036b29c844f8c725698d4ebbf453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1986</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Clonidine - adverse effects</topic><topic>Clonidine - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Muscle Spasticity - drug therapy</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Quadriplegia - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MAYNARD, F. M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Paraplegia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MAYNARD, F. M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early clinical experience with clonidine in spinal spasticity</atitle><jtitle>Paraplegia</jtitle><addtitle>Paraplegia</addtitle><date>1986-06</date><risdate>1986</risdate><volume>24</volume><issue>3</issue><spage>175</spage><epage>182</epage><pages>175-182</pages><issn>0031-1758</issn><issn>1362-4393</issn><eissn>1476-5624</eissn><coden>PRPLBL</coden><abstract>The centrally active, alpha-2 adrenergic receptor agonist clonidine was given to 12 spinal cord injury patients with problematic spasticity not adequately controlled by recognized spasmolytic drug therapy. Five patients had an excellent reduction and 2 patients had some reduction in clinical spasticity (average dose 0.39 mg daily). Four of the 7 responders discontinued clonidine because of adverse reactions after an average of ten weeks of therapy. Three responders have continued to tolerate the drug well with excellent control of spasticity for 18 to 34 months. Five patients had no change in clinical spasticity (average dose of 0.24 mg daily). Three of the non-responders discontinued clonidine because of adverse reactions after an average of three weeks of therapy. Significant associated adverse reactions included syncopal seizures (3), cerebrovascular accident (1), deep vein thrombosis (1), autonomic hyperreflexia (3), lethargy/drowsiness (3), and nausea/vomiting (1). Possible mechanisms of action for clonidine to affect spasticity and the unstable cardiovascular system of quadriplegics is discussed. While spinal cord injured patients with severe spasticity may benefit from clonidine, great caution is recommended during its use until further study establishes safe parameters of administration and efficacy is confirmed on controlled studies.</abstract><cop>Basingstoke</cop><pub>Macmillan</pub><pmid>3748598</pmid><doi>10.1038/sc.1986.24</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0031-1758
ispartof Paraplegia, 1986-06, Vol.24 (3), p.175-182
issn 0031-1758
1362-4393
1476-5624
language eng
recordid cdi_crossref_primary_10_1038_sc_1986_24
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Adult
Aged
Biological and medical sciences
Clonidine - adverse effects
Clonidine - therapeutic use
Female
Humans
Male
Medical sciences
Miscellaneous
Muscle Spasticity - drug therapy
Neuropharmacology
Pharmacology. Drug treatments
Quadriplegia - drug therapy
title Early clinical experience with clonidine in spinal spasticity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T12%3A28%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20clinical%20experience%20with%20clonidine%20in%20spinal%20spasticity&rft.jtitle=Paraplegia&rft.au=MAYNARD,%20F.%20M&rft.date=1986-06&rft.volume=24&rft.issue=3&rft.spage=175&rft.epage=182&rft.pages=175-182&rft.issn=0031-1758&rft.eissn=1476-5624&rft.coden=PRPLBL&rft_id=info:doi/10.1038/sc.1986.24&rft_dat=%3Cpubmed_cross%3E3748598%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/3748598&rfr_iscdi=true